BRKR stock icon

Bruker
BRKR

$65.42
0.91%
 

About: Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.

Employees: 9,707

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 8 analysts
0
News positive %
of 8 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

1,475% more call options, than puts

Call options by funds: $22.8M | Put options by funds: $1.45M

100% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2023] → 6 (+3) [Q1 2024]

51% more first-time investments, than exits

New positions opened: 68 | Existing positions closed: 45

28% more capital invested

Capital invested by funds: $8.04B [Q4 2023] → $10.3B (+$2.26B) [Q1 2024]

21% more repeat investments, than reductions

Existing positions increased: 146 | Existing positions reduced: 121

7% more funds holding

Funds holding: 352 [Q4 2023] → 375 (+23) [Q1 2024]

0.6% more ownership

Funds ownership: 79.06% [Q4 2023] → 79.65% (+0.6%) [Q1 2024]

Research analyst outlook

8 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$74
13%
upside
Avg. target
$88
34%
upside
High target
$102
56%
upside

8 analyst ratings

positive
63%
neutral
25%
negative
13%
Stifel
Daniel Arias
18%upside
$77
Hold
Maintained
20 May 2024
B of A Securities
Derik De Bruin
38%upside
$90
Buy
Maintained
20 May 2024
Goldman Sachs
Matthew Sykes
13%upside
$74
Sell
Maintained
10 Apr 2024
UBS
John Sourbeer
56%upside
$102
Buy
Maintained
1 Mar 2024
UBS
John Sourbeer
44%upside
$94
Buy
Maintained
15 Feb 2024

Financial journalist opinion

Based on 8 articles about BRKR published over the past 30 days